TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30759467

Group type: EXPERIMENTAL
Intervention: Rotatable sphincterotome
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional sphincterotome
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 200
Study: 28946832

Group type: EXPERIMENTAL
Intervention: Endovascular therapy plus medical management
Number of subjects: 476

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 476
Study: 26508752

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) within REVASCAT trial
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) outside REVASCAT trial
Number of subjects: 2576

Group type: COMPARATOR
Intervention: Intravenous thrombolysis only
Number of subjects: 2576
Study: 23570501

Group type: EXPERIMENTAL
Intervention: E-CMF (epirubicin-containing chemotherapy)
Number of subjects: 288

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate and fluorouracil)
Number of subjects: 288
Study: 21448662

Group type: EXPERIMENTAL
Intervention: Computer-assisted gap balancing technique
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional measured resection technique
Number of subjects: 140
Study: 19185642

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 17431226

Group type: EXPERIMENTAL
Intervention: Women with severe pulmonary emphysema
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Men with severe pulmonary emphysema
Number of subjects: 1053
Study: 17133300

Group type: EXPERIMENTAL
Intervention: Oral yohimbine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 12733777

Group type: EXPERIMENTAL
Intervention: Oral appliances
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maxillofacial surgery
Number of subjects: 0
Study: 10325911

Group type: EXPERIMENTAL
Intervention: Beta agonist reduction group (terbutaline dose reduced from 2500 to 500 micrograms/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (terbutaline dose reduced from 3000 to 2250 micrograms/day)
Number of subjects: 33
Study: 7573829

Group type: EXPERIMENTAL
Intervention: Immunotherapy with depot grass pollen extract (Phleum pratense, Alutard SQ)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continued injection treatment (immunotherapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 40
Study: 1904354

Group type: EXPERIMENTAL
Intervention: L-deprenyl (10 mg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 6110955

Group type: EXPERIMENTAL
Intervention: Low-dose cisplatin and chlorambucil
Number of subjects: 98

Group type: COMPARATOR
Intervention: Low-dose cisplatin, chlorambucil, and doxorubicin
Number of subjects: 98
Study: 29471839

Group type: EXPERIMENTAL
Intervention: Optimized follow up by nursing personnel from the vascular neurology department including therapeutic follow up and a training program on secondary prevention directed to the patient and a caregiving member of their social circle.
Number of subjects: 410

Group type: COMPARATOR
Intervention: Usual follow up done by the patient's general practitioner after classical information on secondary prevention of risk factors during hospitalization.
Number of subjects: 410
Study: 27094158

Group type: EXPERIMENTAL
Intervention: Poor self-rated health (SRH)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Good self-rated health (SRH)
Number of subjects: 321
Study: 25925343

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22956509

Group type: EXPERIMENTAL
Intervention: Low serum levels of IL-17 (below the median)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: High soluble VCAM-1 (sVCAM-1) levels
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: IL-17 levels below the median
Number of subjects: 981
Study: 20961444

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Maintenance anti-depressant treatment (m-ADM)
Number of subjects: 420
Study: 17934830

Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: omeprazole 20 mg
Number of subjects: 3
Study: 15902162

Group type: EXPERIMENTAL
Intervention: Perineometer measurements of maximum squeeze pressure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perineometer measurements of average pressure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perineometer measurements of total duration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Brink assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perineometer measurements
Number of subjects: 100
Study: 12638112

Group type: EXPERIMENTAL
Intervention: Children after TBI
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 10596994

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia (B, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (C, n = 10)
Number of subjects: 20
Study: 8768182

Group type: EXPERIMENTAL
Intervention: Polar projection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parallel projection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random mechanism
Number of subjects: 0
Study: 1992363

Group type: EXPERIMENTAL
Intervention: Asymptomatic (AS+)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: AIDS/ARC
Number of subjects: 18
Study: 7141754

Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg rectal pretreatment)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (300 mg)
Number of subjects: 8
Study: 31924519

Group type: EXPERIMENTAL
Intervention: Early rehabilitation (immediate physical therapy for passive and active ROM)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Delayed rehabilitation (no ROM for 6 weeks)
Number of subjects: 107
Study: 30036672

Group type: EXPERIMENTAL
Intervention: Clofazimine (100 mg per day)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 156
Study: 28193599

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate ketogenic diet and lifestyle recommendations (n=12)
Number of subjects: 25
Study: 25963775

Group type: EXPERIMENTAL
Intervention: Supervision (tele‐conferencing or tape‐based)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Workshop only
Number of subjects: 96
Study: 23377024

Group type: EXPERIMENTAL
Intervention: Caffeine 0 mg (no caffeine) with 4.3% alcohol
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Caffeine 62.5 mg with 4.3% alcohol
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Caffeine 125 mg with 4.3% alcohol
Number of subjects: 146

Group type: COMPARATOR
Intervention: Caffeine 0 mg (no caffeine) with no alcohol
Number of subjects: 146

Group type: COMPARATOR
Intervention: Caffeine 62.5 mg with no alcohol
Number of subjects: 146

Group type: COMPARATOR
Intervention: Caffeine 125 mg with no alcohol
Number of subjects: 146
Study: 21549138

Group type: EXPERIMENTAL
Intervention: 70% cocoa chocolate
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 85% cocoa chocolate
Number of subjects: 280

Group type: COMPARATOR
Intervention: white chocolate (control)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: chocolate samples with high sugar and cocoa content
Number of subjects: 280
Study: 19767090

Group type: EXPERIMENTAL
Intervention: Oestrogen plus progestin (0.625 mg conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study: 17573745

Group type: EXPERIMENTAL
Intervention: Parenteral Gln (1 g/kg/day) with enteral nutrition (Ensure)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group received only enteral nutrition (Ensure)
Number of subjects: 109
Study: 14739803

Group type: EXPERIMENTAL
Intervention: Ketamine at 200 ng/ml (analgesic, subanesthetic)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketamine at 50 ng/ml (subanalgesic)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 11770699

Group type: EXPERIMENTAL
Intervention: C(-444) allele
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 119
Study: 9248315

Group type: EXPERIMENTAL
Intervention: MOS SF‐36 Health Survey (SF‐36)
Number of subjects: 163
Study: 8507122

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg twice daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg twice daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Cholestyramine 24 g daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Cholestyramine 12 g twice daily with Pravastatin 40 mg
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 or 80 mg daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Cholestyramine alone
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Combined therapy (Cholestyramine + Pravastatin)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 311

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 311

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 311
Study: 3034026

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Captopril 12.5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Captopril 25 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 10
Study: 29996833

Group type: COMPARATOR
Intervention: Post-discharge malaria chemoprevention (PMC) with antimalarial drugs for 3 months post-discharge.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based delivery of PMC.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of health cards for treatment reminders.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text message reminders for PMC delivery.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine as the antimalarial drug.
Number of subjects: 0
Study: 26939695

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) hang-up visits at intervals of 1-3, 5-7, 10-12, 15-17 days
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) hang-up visits
Number of subjects: 540

Group type: COMPARATOR
Intervention: No CHW hang-up visit (control group)
Number of subjects: 540
Study: 25079863

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 22220768

Group type: EXPERIMENTAL
Intervention: GBR procedure
Number of subjects: 91

Group type: COMPARATOR
Intervention: Non-GBR procedure
Number of subjects: 91
Study: 20513271

Group type: EXPERIMENTAL
Intervention: FIN‐D2D lifestyle intervention in primary health-care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FINNAIR workplace-targeted intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GOAL community-based prevention programme
Number of subjects: 0
Study: 18480672

Group type: EXPERIMENTAL
Intervention: Upstream tirofiban therapy
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Downstream tirofiban therapy
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (primary PCI treatment alone)
Number of subjects: 172
Study: 15706546

Group type: EXPERIMENTAL
Intervention: Leg-loading exercise protocol (5 progression levels)
Number of subjects: 18
Study: 14520850

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg twice a day
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Metoprolol 25-50 mg twice a day
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5-10 mg once a day
Number of subjects: 104
Study: 11755543

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (n = 105)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (n = 106)
Number of subjects: 211
Study: 9371346

Group type: EXPERIMENTAL
Intervention: Saquinavir
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Triple combination (saquinavir, zidovudine, zalcitabine)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saquinavir and zidovudine combination
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Zalcitabine
Number of subjects: 300
Study: 1531855

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) combined with chemotherapy
Number of subjects: 144

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 144
Study: 3758141

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional diuretic therapy
Number of subjects: 48
Study: 31663690

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2 μg kg‐1 perioperatively)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 24
Study: 29339594

Group type: EXPERIMENTAL
Intervention: Crenotherapy (group B)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Treadmill exercise (group A)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 98
Study: 25201095

Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (therapy dog visitation for 15 minutes before physical therapy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard postoperative physical therapy regimens
Number of subjects: 72
Study: 23513398

Group type: EXPERIMENTAL
Intervention: Vertical position
Number of subjects: 164

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 164
Study: 20934440

Group type: EXPERIMENTAL
Intervention: 22mg yohimbine hydrochloride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19454916

Group type: EXPERIMENTAL
Intervention: Eight-session parent intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 71
Study: 16434463

Group type: EXPERIMENTAL
Intervention: 20% lipid/heparin infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: saline/heparin infusion
Number of subjects: 8
Study: 15232330

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine 20 mg/d
Number of subjects: 0
Study: 11306523

Group type: EXPERIMENTAL
Intervention: AMI patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: UAP patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: SAP patients
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: UAP patients (in atherectomy specimens)
Number of subjects: 135
Study: 9645896

Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (1.5 mg/kg body weight, maximum 150 mg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intravenous sotalol (1.5 mg/kg body weight, maximum 150 mg)
Number of subjects: 106
Study: 7840710

Group type: EXPERIMENTAL
Intervention: Comprehensive therapy including indomethacin, essential and dimephosphone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combined use of pathogenetic and antibacterial drugs (monomycin, kanamycin, polymyxin, gentamicin)
Number of subjects: 70
Study: 2906248

Group type: EXPERIMENTAL
Intervention: N‐696 (30 mg/d for 7 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Propranolol (60 mg/d for 7 days)
Number of subjects: 14
Study: 1850964

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1092749

Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30655188

Group type: EXPERIMENTAL
Intervention: Living in nursing home
Number of subjects: 72

Group type: COMPARATOR
Intervention: Living in own home
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Increased ultraviolet index exposure
Number of subjects: 72
Study: 30232597

Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg for 14 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 23
Study: 29201297

Group type: EXPERIMENTAL
Intervention: Polmacoxib 2 mg
Number of subjects: 362

Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 25311357

Group type: EXPERIMENTAL
Intervention: DWP450 (20 U)
Number of subjects: 268

Group type: COMPARATOR
Intervention: OBoNT (20 U)
Number of subjects: 268

Group type: COMPARATOR
Intervention: DWP450 and OBoNT
Number of subjects: 268
Study: 23819122

Group type: EXPERIMENTAL
Intervention: Mydriasert insert (0.28 mg of tropicamide and 5.4 mg of phenylephrine hydrochloride)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional mydriatic drops (tropicamide 1%, phenylephrine 10%, and cyclopentolate 1%)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mydriasert insert
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional mydriatic drops
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mydriasert insert and Conventional mydriatic drops
Number of subjects: 70
Study: 21577031

Group type: EXPERIMENTAL
Intervention: Aerosolized liposomal amphotericin B (lipAmB)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 98
Study: 19922034

Group type: EXPERIMENTAL
Intervention: Aerobic exercise using Dance Dance Revolution (DDR) for 12 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-exercising delayed-treatment control group (DTC)
Number of subjects: 35
Study: 16773694

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (two 600 mg doses orally 24 and 12 hours before ERCP and 600 mg IV, twice a day for two days after ERCP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Isotonic saline (IV, twice a day for two days after ERCP)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 106
Study: 15519704

Group type: EXPERIMENTAL
Intervention: Viatim vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hepatyrix vaccine
Number of subjects: 0
Study: 11760147

Group type: EXPERIMENTAL
Intervention: Oral ondansetron (8 mg PO every 8 hours)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oral granisetron (1 mg PO every 12 hours)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: IV ondansetron (32 mg IV every 24 hours)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cost analysis among all arms
Number of subjects: 102
Study: 9919425

Group type: EXPERIMENTAL
Intervention: Exercise training (three times a week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (continued regular treatment)
Number of subjects: 0
Study: 8115153

Group type: EXPERIMENTAL
Intervention: Oral melatonin treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study: 3043418

Group type: EXPERIMENTAL
Intervention: Caffeine consumption
Number of subjects: 10064

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 10064
Study: 31335363

Group type: EXPERIMENTAL
Intervention: Venoarterial extracorporeal membrane oxygenation with concomitant Impella (ECPELLA)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Venoarterial extracorporeal membrane oxygenation (VA ECMO) alone
Number of subjects: 425
Study: 30036177

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose for pre-operative haemoglobin optimisation
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Non-optimisation control arm
Number of subjects: 20000
Study: 27214731

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 94459

Group type: EXPERIMENTAL
Intervention: Standard air insufflation
Number of subjects: 94459

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) insufflation
Number of subjects: 94459
Study: 25622725

Group type: EXPERIMENTAL
Intervention: Tooth brushing + mouth washing with chlorine dioxide + tongue cleaning
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tooth brushing + mouth washing with chlorine dioxide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tooth brushing alone
Number of subjects: 30
Study: 24104372

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment (1g/m2 d 1, 8, 15, q 4 weeks for 6 months)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment
Number of subjects: 368
Study: 20628405

Group type: EXPERIMENTAL
Intervention: 140 mg silybin (Legalon Forte) with a vegetarian meal containing 13.9 mg iron
Number of subjects: 10

Group type: COMPARATOR
Intervention: 200 ml water
Number of subjects: 10

Group type: COMPARATOR
Intervention: 200 ml tea
Number of subjects: 10
Study: 18172039

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin 10 to 20 mg/d
Number of subjects: 5356

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 5356

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin 10 to 20 mg/d (women ≥ 60 years)
Number of subjects: 5356

Group type: COMPARATOR
Intervention: Diet alone (women ≥ 60 years)
Number of subjects: 5356
Study: 16948756

Group type: EXPERIMENTAL
Intervention: Combination group (amiodarone 5 mg/kg and MgSO(4) 1.5 g)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Amiodarone group (amiodarone 5 mg/kg)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 136
Study: 14558738

Group type: EXPERIMENTAL
Intervention: Cefaclor 375 mg twice daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice daily
Number of subjects: 300
Study: 11166781

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate
Number of subjects: 35
Study: 9505239

Group type: EXPERIMENTAL
Intervention: Protein enriched product
Number of subjects: 50

Group type: COMPARATOR
Intervention: Carbohydrate product
Number of subjects: 50